VIDEO: DAVIO 2 trial for wet AMD meets primary endpoint
Click Here to Manage Email Alerts
FORT LAUDERDALE, Fla. — In this Healio Video Perspective from the Retina World Congress, Ashkan M. Abbey, MD, shares topline data from the phase 2 DAVIO 2 trial investigating Duravyu for wet age-related macular degeneration.
The study met its primary endpoint of noninferiority to the standard of care in best corrected visual acuity at week 32 in patients who received Duravyu (vorolanib intravitreal insert, EyePoint Pharmaceuticals). Abbey also discussed the treatment burden and safety results.
“We’re looking at potential for a new therapy that allows us to treat and maintain our patients who are receiving anti-VEGF injections, allowing them possibly to have a significant reduction in treatment burden with just one additional injection every maybe 6 to 9 months,” he said.
Collapse
Abbey A, et al. DAVIO 2 clinical trial. Presented at: Retina World Congress; May 9-12, 2024; Fort Lauderdale, Florida.
Read more about
Click Here to Manage Email Alerts